Monthly Archives: January 2015
One terrible mistake that most people do in decision making is to examine facts with financial myopia. Significant investment opportunities might be lost by the use of this monetary biased criterion in decision making. From an investment point of view that’s why its not used at all in venture capital funding AND from a policy point of view that’s why fiscal and monetary policies must be distinguished. A strategic view is needed in policy making. Finance can only valuate a small part of available options and opportunities while those valuations are heavily distorted in a financial distressed environment (like that we are now and even with options theory advances). I feel and expect that this myopia is completely absent from the current Greek Policy glances. EU policy tried to connect fiscal and monetary measures through restructuring but restructuring was just examined UNDER this financial myopia and not strategically and this was the biggest mistake. The importance of Restructuring has to be examined in a strategic alignment framework within which finance plays a small part among other important strategic determinants. For further on this issue you can read some of my publications around 1996-1998 that currently i have in mind, some in Greek some in English: “Αναδιάρθρωση Παραγωγής: H Αλληλεπίδραση της Πληροφοριακής με την Οργάνωση και Στρατηγική των Επιχειρήσεων” 1996 Doctorate submitted in the University ofMacedonia, “‘Αναδιάρθρωση της Παραγωγής στις ΜΜΕ: Η Στρατηγική της Κατασκευαστική Ευελιξίας’, Δημοσιεύτηκε στο Μάνατζμεντ Μικρομεσαίων Επιχειρήσεων, Πανεπιστημιακές Εκδόσεις Κρήτης, 1996. ISBN: 960-7309-98-7”, ‘A Model for the Internal Structure of Manufacturing Firms’: 7th International Conference on Management of Technology, 16-20 Febr. 1998. Orlando, Florida, USA. ‘Manufacturing Strategies and Financial Performance: The Effect of Advanced Information Technology’, published in International Journal of Management Science, OMEGA, V36, (2008) ,p107-121. ‘A DSS Model That Aligns Business Strategy and Business Structure with Advanced Information Technology: A Case Study’ in Annals of Cases on Information Technology, Volume 6/2004. I am happy to see that restructuring named 2 of the new ministries and this gives the starting intention. Good luck to all of us.
On April 9, three weeks after Josh got into the brincidofovir trial, Moch stepped down as CEO. The company says he resigned. Moch says he was replaced and can’t comment in detail about his departure other than to say he would have “loved to continue to be CEO, but the board felt otherwise.” Chimerix declined to comment beyond its press release announcing Moch’s departure and his replacement. “We are now entering a critical stage of the clinical development of brincidofovir,” the release said. “Our goal is to complete the requirements for regulatory approval of brincidofovir as rapidly as possible.”